[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Pullarkat V, Veliz L, Chang K, Mohrbacher A, Teotico AL, Forman SJ, Slovak ML: Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus. J Clin Pathol; 2007 May;60(5):562-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.
  • These tumours can, on occasion, occur without concurrent or antecedent leukaemia.
  • An unusual case of therapy-related acute myeloid leukaemia (t-AML) presenting as isolated monoblastic myeloid sarcoma of the uterus in a patient who had received adjuvant chemotherapy for breast cancer is presented.
  • Fluorescence in situ hybridisation analysis performed on paraffin-wax-embedded tumour tissue revealed a mixed-lineage leukaemia (MLL) gene rearrangement, supporting the association of this malignancy with prior chemotherapy.
  • This case illustrates that t-AML can rarely present as isolated extramedullary tumours, and the detection of specific chromosomal abnormalities in these myeloid sarcomas can be useful for risk assessment and guiding definitive therapy.

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Nov;114(5):807-11 [11068557.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):255-76 [11378539.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2151-3 [12533040.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):271-82 [14615822.001]
  • [Cites] Leukemia. 2005 Feb;19(2):183-90 [15618964.001]
  • [Cites] Urology. 1986 Mar;27(3):268-70 [3082059.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):128-37 [1634133.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):431-43 [7572794.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] Leuk Res. 2004 Nov;28(11):1165-9 [15380340.001]
  • (PMID = 17513515.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / 2 P01 CA030206-24A1; United States / NCI NIH HHS / CA / 5P30 CA33572
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994540
  •  go-up   go-down


2. Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC: Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol; 2008 Dec;66(6):826-37
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
  • AIMS: To investigate the population pharmacokinetics of 6-mercaptopurine (6-MP) active metabolites in paediatric patients with acute lymphoblastic leukaemia (ALL) and examine the effects of various genetic polymorphisms on the disposition of these metabolites.
  • METHODS: Data were collected prospectively from 19 paediatric patients with ALL (n = 75 samples, 150 concentrations) who received 6-MP maintenance chemotherapy (titrated to a target dose of 75 mg m(-2) day(-1)).
  • Population pharmacokinetic analysis was performed with the nonlinear mixed effects modelling program (nonmem) to determine the population mean parameter estimate of clearance for the active metabolites.
  • RESULTS: The developed model revealed considerable interindividual variability (IIV) in the clearance of 6-MP active metabolites [6-thioguanine nucleotides (6-TGNs) and 6-methylmercaptopurine nucleotides (6-mMPNs)].
  • CONCLUSIONS: The developed pharmacokinetic model (if successful at external validation) would offer a more rational dosing approach for 6-MP than the traditional empirical method since it combines the current practice of using body surface area in 6-MP dosing with a pharmacogenetically guided dosing based on TPMT genotype.
  • [MeSH-major] 6-Mercaptopurine / analogs & derivatives. Antimetabolites, Antineoplastic / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Methyltransferases / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Genotype. Humans. Male. Metabolic Clearance Rate / genetics. Models, Biological. Pharmacogenetics. Prospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):1983-5 [10580012.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Feb;19(1):23-37 [17305252.001]
  • [Cites] J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12 [7310648.001]
  • [Cites] N Engl J Med. 1983 Apr 28;308(17):1005-9 [6572786.001]
  • [Cites] Clin Pharmacol Ther. 1986 Sep;40(3):287-92 [3461899.001]
  • [Cites] Biochem Pharmacol. 1986 Oct 15;35(20):3533-41 [3533081.001]
  • [Cites] Science. 1989 Apr 7;244(4900):41-7 [2649979.001]
  • [Cites] Clin Pharmacokinet. 1989 Jun;16(6):327-36 [2661101.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1816-23 [2585022.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3 [2520314.001]
  • [Cites] Br J Cancer Suppl. 1992 Aug;18:S23-9 [1503923.001]
  • [Cites] Eur J Clin Pharmacol. 1992;43(4):329-39 [1451710.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):411-8 [8258188.001]
  • [Cites] Clin Pharmacokinet. 1996 May;30(5):329-32 [8743333.001]
  • [Cites] Eur J Pharm Sci. 1999 Aug;8(4):329-34 [10425383.001]
  • [Cites] Cancer Res. 1958 Aug;18(7):853-6 [13573353.001]
  • [Cites] Med Sci Monit. 2004 Nov;10(11):RA247-54 [15507865.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1629-38 [16550163.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29 [16918876.001]
  • [Cites] Pediatr Int. 2001 Dec;43(6):673-7 [11737747.001]
  • (PMID = 18823306.001).
  • [ISSN] 1365-2125
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 6V404DV25O / 6-methylthiopurine; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  • [Other-IDs] NLM/ PMC2675766
  •  go-up   go-down


3. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol; 2010 Jun;11(6):543-52
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
  • BACKGROUND: We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on genetic abnormalities of the leukaemic cells and measurements of minimal residual disease (MRD) done by flow cytometry during treatment.
  • METHODS: From Oct 13, 2002, to June 19, 2008, 232 patients with de-novo AML (n=206), therapy-related or myelodysplasia-related AML (n=12), or mixed-lineage leukaemia (n=14) were enrolled at eight centres.
  • Induction 2 consisted of ADE with or without gemtuzumab ozogamicin (GO anti-CD33 monoclonal antibody); consolidation therapy included three additional courses of chemotherapy or haematopoietic stem-cell transplantation (HSCT).
  • Both MRD and genetic abnormalities at diagnosis were used to determine the final risk classification.
  • Low-risk patients (n=68) received five courses of chemotherapy, whereas high-risk patients (n=79), and standard-risk patients (n=69) with matched sibling donors, were eligible for HSCT (done for 48 high-risk and eight standard-risk patients).
  • Other analyses were limited to the 216 patients with AML, excluding those with mixed-lineage leukaemia.
  • Induction failures included two deaths from toxic effects and ten cases of resistant leukaemia.
  • The 6-month cumulative incidence of grade 3 or higher infection was 79.3% (SE 4.0) for patients in the high-dose group and 75.5% (4.2) for the low-dose group.
  • 3-year event-free survival and overall survival were 63.0% (SE 4.1) and 71.1% (3.8), respectively.
  • 80% (155 of 193) of patients achieved MRD of less than 0.1% after induction 2, and the cumulative incidence of relapse for this group was 17% (SE 3).
  • INTERPRETATION: Our findings suggest that the use of targeted chemotherapy and HSCT, in the context of a comprehensive risk-stratification strategy based on genetic features and MRD findings, can improve outcome in patients with childhood AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adolescent. Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cytarabine / administration & dosage. Cytogenetic Analysis. Daunorubicin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Flow Cytometry. Humans. Infant. Infant, Newborn. Male. Neoplasm, Residual. Remission Induction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):955-9 [20085940.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2302-9 [11981001.001]
  • [Cites] Lancet. 2002 May 11;359(9318):1686-9 [12020548.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):243-52 [14531905.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2715-22 [14669294.001]
  • [Cites] J Chronic Dis. 1974 Sep;27(7-8):365-75 [4612056.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1710-7 [8634416.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2090-100 [16304571.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2495-502 [16639734.001]
  • [Cites] Blood. 2006 Jul 1;108(1):74-80 [16537811.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):116-24 [16721819.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3686-92 [16877738.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4499-506 [16983120.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):376-82 [18459178.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4944-51 [18606980.001]
  • [Cites] Blood. 2009 May 21;113(21):5083-9 [19131545.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Blood. 2009 Jul 30;114(5):937-51 [19357394.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1410-6 [19242495.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):4007-13 [19620491.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:385-95 [20008224.001]
  • [CommentIn] Lancet Oncol. 2010 Jun;11(6):502-3 [20522371.001]
  • (PMID = 20451454.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00136084
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA115422; United States / NCI NIH HHS / CA / R01 CA115422-02
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 93NS566KF7 / gemtuzumab; ZS7284E0ZP / Daunorubicin; DAV regimen
  • [Other-IDs] NLM/ NIHMS319127; NLM/ PMC3171799
  •  go-up   go-down


Advertisement
4. Huang F, Meng FY, Xue B, Liu XL, Zhang Y, Ye CX, Zhang X: [Therapeutic effects of chemotherapeutic regimen with pirarubicin for adult high-risk acute leukemia]. Di Yi Jun Yi Da Xue Xue Bao; 2004 Jul;24(7):768-70
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effects of chemotherapeutic regimen with pirarubicin for adult high-risk acute leukemia].
  • OBJECTIVE: To evaluate the therapeutic effects of chemotherapeutic regimen with pirarubicin in the management of adult high-risk acute leukemia.
  • METHODS: Twenty-nine high-risk acute leukemia patients were selected as the treatment group and another 29 patients with similar pretreatment conditions as the control group.
  • In the treatment group, 18 patients had acute non-lymphocytic leukemia (ANLL), and 8 had acute lymphocytic leukemia (ALL) and 3 had mixed leukemia, all received treatment regimens with pirarubicin+cytarabine, vincristine+pirarubicin+prednisone, Vincristine+pirarubicin+L-asparaginase (L)+prednisone or pirarubicin+cytarabine+vincristine+prednisone.
  • Routine therapeutic regimens were adopted in the management of the control.
  • RESULTS: In ANLL patients, the overall remission rate was significantly higher in the treatment group than in the control group (77.78% vs 44.44%, P=0.031).
  • Patients in the treatment group had greater marrow suppression and higher incidence of infections than the control group (P=0.012).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15257898.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


5. Gupta S, Jen J, Kolz K, Cutler D: Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia. Br J Clin Pharmacol; 2007 Mar;63(3):292-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia.
  • AIMS: To assess the dose selection using population pharmacokinetics of Pegylated Intron-alpha2b (PEG-Intron) in patients with chronic myelogenous leukaemia (CML).
  • METHODS: PEG-Intron 3-6 microg kg(-1) was administered subcutaneously once a week and blood samples were collected up to 48 weeks of treatment.
  • Nonlinear mixed-effects modelling was used to analyse the sparsely sampled concentration data from a clinical efficacy trial.
  • The clearance at treatment week 4 was 42.3 l day(-1) (patients with CLcr 120 ml min(-1)) with interpatient variability 30%.
  • At treatment week 48, the clearance value was reduced to 69% of its week 4 value.
  • CONCLUSION: The dose of PEG-Intron 6.0 microg kg(-1) week(-1) appeared appropriate in the treatment of patients with CML.
  • [MeSH-major] Antiviral Agents / therapeutic use. Interferon-alpha / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacol Ther. 2000 Nov;68(5):556-67 [11103758.001]
  • [Cites] Clin Pharmacol Ther. 2001 Jun;69(6):407-21 [11406738.001]
  • [Cites] Hepatology. 2001 Aug;34(2):395-403 [11481625.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1708-13 [11535501.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Ann Intern Med. 1999 Aug 3;131(3):207-19 [10428738.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Ann Intern Med. 1991 Apr 1;114(7):532-8 [2001086.001]
  • [Cites] Ann Intern Med. 1995 Feb 15;122(4):254-61 [7825760.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3069-81 [8605319.001]
  • [Cites] J Clin Pharmacol. 2002 Oct;42(10):1109-15 [12362925.001]
  • (PMID = 16939523.001).
  • [ISSN] 0306-5251
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC2000735
  •  go-up   go-down


6. Ng A, Taylor GM, Wynn RF, Eden OB: Effects of topoisomerase 2 inhibitors on the MLL gene in children receiving chemotherapy: a prospective study. Leukemia; 2005 Feb;19(2):253-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of topoisomerase 2 inhibitors on the MLL gene in children receiving chemotherapy: a prospective study.
  • The molecular effects of etoposide in haemopoietic cells suggest that mixed lineage leukaemia (MLL) abnormalities can be biomarkers of patient susceptibility to the genotoxic effects of topoisomerase 2 (topo 2) inhibitors.
  • We have prospectively studied treatment-related MLL cleavage and rearrangement in serial samples from 71 children receiving chemotherapy, using Southern blot analysis and panhandle PCR.
  • The results were related to patient demographics, treatment details and outcome.
  • MLL cleavage was identified in six bone marrow samples from five patients 2-10 months after the start of therapy.
  • Three children with low percentage (23-30%) cleavage remained well and two were still receiving treatment at study completion.
  • One child with two consecutively positive samples and higher level of MLL cleavage (45-48%) died from treatment-related toxicities and relapsed leukaemia.
  • A patient with haemophagocytic lymphohistiocytosis developed the highest level of MLL cleavage (50%) at 3 months and a treatment-related leukaemia with MLL rearrangement 6 months after the start of treatment.
  • [MeSH-major] DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / genetics. Enzyme Inhibitors / therapeutic use. Leukemia / drug therapy. Leukemia / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Continental Population Groups. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Infant. Mutation / genetics. Myeloid-Lymphoid Leukemia Protein. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592432.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


7. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet; 2007 Jul 21;370(9583):240-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
  • BACKGROUND: Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children.
  • We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants.
  • Eligible patients were stratified for risk according to their peripheral blood response to a 7-day prednisone prophase, and then given a hybrid regimen based on the standard protocol for acute lymphoblastic leukaemia, with some elements designed for treatment of acute myeloid leukaemia.
  • Before the maintenance phase, a subset of patients in complete remission were randomly assigned to receive either standard treatment or a more intensive chemotherapy course with high-dose cytarabine and methotrexate.
  • The primary outcomes were event-free survival (EFS) for the initial cohort of patients and disease-free survival (DFS) for the patients randomly assigned to a treatment group.
  • FINDINGS: In the 482 enrolled patients who underwent hybrid treatment, 260 (58%) were in complete remission at a median follow-up of 38 (range 1-78) months, and EFS at 4 years was 47.0% (SE 2.6, 95% CI 41.9-52.1).
  • Of 445 patients in complete remission after 5 weeks of induction treatment, 191 were randomised: 95 patients to receive a late intensification course, and 96 to a control group.
  • At a median follow-up of 42 (range 1-73) months, 60 patients in the treatment group and 57 controls were disease-free.
  • DFS at 4 years did not differ between the two groups (60.9% [SE 5.2] for treatment group vs 57.0% [5.5] for controls; p=0.81).
  • During the intensification phase, of 71 patients randomly assigned to the treatment group, and for whom toxicity data were available, 35 (49%) had infections, 21 (30%) patients had mucositis, 22 (31%) patients had toxic effects on the liver, and 2 (3%) had neurotoxicity.
  • All types of rearrangements in the (mixed lineage leukaemia) MLL gene, very high white blood cell count, age of younger than 6 months, and a poor response to the prednisone prophase were independently associated with inferior outcomes.
  • INTERPRETATION: Patients treated with our hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL.
  • Delayed intensification of chemotherapy did not benefit patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Jul 21;370(9583):198-200 [17658376.001]
  • (PMID = 17658395.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00015873; ISRCTN/ ISRCTN24251487
  • [Grant] United Kingdom / Medical Research Council / / G0300130
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, García MJ: Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet; 2006;45(12):1227-38
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
  • OBJECTIVE: To develop and a priori validate a methotrexate population pharmacokinetic model in children with acute lymphoblastic leukaemia (ALL), receiving high-dose methotrexate followed by folinic acid rescue, identifying the covariates that could explain part of the pharmacokinetic variability of methotrexate.
  • METHODS: The study was carried out in 49 children (aged 6 months to 17 years) who received high-dose methotrexate (3 g/m(2) per course) in long-term treatment.
  • In an index group (37 individuals; 1236 methotrexate plasma concentrations), a population pharmacokinetic model was developed using a nonlinear mixed-effects model.
  • CONCLUSION: A methotrexate population pharmacokinetic model has been developed for ALL children.
  • The proposed model could be used in Bayesian algorithms with a limited sampling strategy to estimate the systemic exposure of individual patients to methotrexate and adapt both folinic acid rescue and methotrexate dosing accordingly.
  • [MeSH-major] Methotrexate / pharmacokinetics. Models, Biological. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Age Factors. Alanine Transaminase / blood. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspartate Aminotransferases / blood. Bayes Theorem. Body Weight. Child. Child, Preschool. Creatinine / blood. Dose-Response Relationship, Drug. Female. Humans. Infant. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Metabolic Clearance Rate. Monte Carlo Method. Treatment Outcome. Vitamin B Complex / administration & dosage

  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1997 May;21(5):435-7 [9225072.001]
  • [Cites] Pediatr Hematol Oncol. 1996 Jul-Aug;13(4):359-67 [8837142.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Eur J Clin Pharmacol. 1980 May;17(5):371-4 [7418714.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):154-9 [7838036.001]
  • [Cites] J Pediatr. 1987 Oct;111(4):606-12 [2958611.001]
  • [Cites] Chemotherapy. 1993 Jul-Aug;39(4):242-7 [8325125.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1667-72 [8040679.001]
  • [Cites] J Pharmacokinet Biopharm. 1985 Feb;13(1):101-15 [3839529.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Dec;52(3):173-97 [15582785.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Nov;58(5):626-33 [16528531.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Mar 25;817(2):139-44 [15686977.001]
  • [Cites] Br J Clin Pharmacol. 1998 Oct;46(4):369-76 [9803986.001]
  • [Cites] Leuk Res. 2000 Mar;24(3):193-9 [10739001.001]
  • [Cites] Leuk Res. 1997 May;21(5):429-34 [9225071.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1081-9 [12008196.001]
  • [Cites] Int J Cancer. 1986 Dec 15;38(6):795-800 [3793260.001]
  • [Cites] Cancer Drug Deliv. 1985 Fall;2(4):271-6 [3864520.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] Lancet. 1984 Feb 18;1(8373):359-62 [6141424.001]
  • [Cites] Fundam Clin Pharmacol. 2002 Aug;16(4):253-62 [12570013.001]
  • [Cites] J Clin Pharm Ther. 2002 Jun;27(3):189-95 [12081632.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4267-71 [2194652.001]
  • [Cites] Clin Pharmacokinet. 2000 Apr;38(4):315-53 [10803455.001]
  • [Cites] Clin Pharmacokinet. 2002;41(13):1095-104 [12403645.001]
  • [Cites] Comput Methods Programs Biomed. 1999 Jan;58(1):51-64 [10195646.001]
  • [Cites] Int J Clin Pharmacol Ther. 1995 Mar;33(3):164-9 [7599915.001]
  • [Cites] Clin Chem. 1996 Aug;42(8 Pt 2):1322-9 [8697606.001]
  • [Cites] J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12 [7310648.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1176-81 [9697870.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):5-13 [3472638.001]
  • [Cites] J Pharmacokinet Biopharm. 1990 Apr;18(2):161-73 [2348382.001]
  • [Cites] Acta Oncol. 1998;37(3):277-84 [9677100.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Apr;51(4):311-20 [12721759.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):851-7 [12792734.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):3020-4 [3479231.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2514-9 [1824248.001]
  • [Cites] Eur J Clin Pharmacol. 1978 Nov 16;14(2):143-7 [720376.001]
  • [Cites] Ther Drug Monit. 1995 Oct;17(5):471-8 [8585110.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2000;:285-302 [11701547.001]
  • [Cites] Drug Intell Clin Pharm. 1982 Nov;16(11):839-42 [6959800.001]
  • [Cites] Fundam Clin Pharmacol. 1999;13(5):595-604 [10520733.001]
  • [Cites] Leukemia. 2000 Feb;14(2):221-5 [10673736.001]
  • [Cites] Eur J Clin Pharmacol. 1990;39(4):377-83 [2076721.001]
  • [Cites] Chronobiol Int. 1992 Dec;9(6):434-8 [1473196.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):695-701 [18282.001]
  • (PMID = 17112298.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; AYI8EX34EU / Creatinine; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Amin P, Shah S, Walker D, Page SR: Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood; two case reports and a literature review. Diabet Med; 2001 Oct;18(10):849-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood; two case reports and a literature review.
  • We report two patients who survived childhood acute lymphoblastic leukaemia (ALL) following treatment with chemotherapy, total body irradiation (TBI) and bone marrow transplantation (BMT).
  • The first case presented with an acute cerebral infarction at 23 years of age and was found to have non-ketotic diabetes and gross mixed hyperlipidaemia; the second presented with non-ketotic diabetes, hypertension, proteinuria and dyslipidaemia at age 16 years.
  • The association of glucose intolerance with other vascular risk factors in young adult survivors of BMT was recently highlighted in a follow-up study of 23 survivors of BMT [1], but none presented with such gross mixed hyperlipidaemia.
  • The improving survival rates of childhood malignancy over the last two decades will present adult physicians with patients who have accelerated vascular risk at a young age who will require early treatment to modify it.
  • [MeSH-major] Cardiovascular Diseases / etiology. Cerebral Infarction / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Combined Modality Therapy. England. European Continental Ancestry Group. Female. Glucose Intolerance / etiology. Human Growth Hormone / deficiency. Human Growth Hormone / therapeutic use. Humans. Male. Ovarian Cysts / etiology. Ovarian Cysts / surgery. Ovariectomy. Radiotherapy. Recurrence. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11678978.001).
  • [ISSN] 0742-3071
  • [Journal-full-title] Diabetic medicine : a journal of the British Diabetic Association
  • [ISO-abbreviation] Diabet. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  • [Number-of-references] 17
  •  go-up   go-down


10. Deslandes E, Chevret S: Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia. Stat Med; 2007 Dec 30;26(30):5411-21
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia.
  • In clinical research, we are often interested in assessing how a biomarker changes with time, and whether it could be used as a surrogate marker when evaluating the efficacy of a new drug.
  • However, when the longitudinal marker is correlated with survival, linear mixed models for longitudinal data may be inappropriate.
  • We present both analyses based on a case study from two randomized clinical trials that enrolled patients with stage A chronic lymphocytic leukaemia (CLL) in order to obtain further insights into these different approaches.
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Biometry / methods. Cell Count / statistics & numerical data. Chlorambucil / therapeutic use. Data Interpretation, Statistical. Disease Progression. France. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukocytes / cytology. Leukocytes / drug effects. Likelihood Functions. Linear Models. Longitudinal Studies. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 John Wiley & Sons, Ltd.
  • (PMID = 18058850.001).
  • [ISSN] 0277-6715
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


11. Main C, Pitt M, Moxham T, Stein K: The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Health Technol Assess; 2010 Oct;14(Suppl. 2):27-32
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
  • This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia (CLL) based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process.
  • The submission's evidence came from a single, unpublished, well-conducted randomised controlled trial (RCT) comparing rituximab in combination with fludarabine and cyclophosphamide (R-FC) with fludarabine and cyclophosphamide (FC) alone for the first-line treatment of CLL.
  • However, the initial significant treatment benefit for R-FC compared with FC for overall survival was not maintained at a slightly longer follow-up time [median 25.4 months; adjusted HR 0.72 (95% CI 0.48 to 1.09)].
  • Response rates, numbers of patients with event-free survival and duration of response all favoured treatment with R-FC.
  • Additional evidence from a mixed-treatment comparison model indicated R-FC to be significantly superior to chlorambucil alone for both PFS and overall and complete response rates.
  • Dose modifications were also more frequent in this arm, but this did not lead to differences in treatment discontinuation.
  • The model used a cycle length of 1 month and a lifetime time horizon.
  • The NICE guidance issued as a result of the STA states that: Rituximab in combination with fludarabine and cyclophosphamide (R-FC) is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide (FC) is considered appropriate.
  • Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047488.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


12. Chen X, Regn S, Raffegerst S, Kolb HJ, Roskrow M: Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol; 2000 Nov;111(2):596-607
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia.
  • Although interferon alpha (IFN-alpha) is able to induce haematological remission in 60-80% of patients with chronic myeloid leukaemia (CML) in early chronic phase, major cytogenetic remissions are only achievable in 30-40%.
  • Recent clinical data suggest that the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) to IFN-alpha therapy can significantly improve the cytogenetic response in some patients, although the mechanism remains unknown.
  • In mixed lymphocyte reactions (MLR), GM/IFN-alpha APCs stimulated the proliferation of allogeneic T cells significantly better than GM/IL-4 APCs.
  • Finally, we assessed the ability of GM/IFN-alpha APCs to induce a leukaemia-specific cytotoxic T-cell response.
  • [MeSH-major] Antigen-Presenting Cells / immunology. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Interferon-alpha / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Lymphocyte Activation. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Cell Differentiation. Cells, Cultured. Cytotoxicity Tests, Immunologic. Enzyme-Linked Immunosorbent Assay. Humans. In Situ Hybridization, Fluorescence. Interleukin-18 / analysis. Interleukin-4 / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11122108.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-18; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


13. Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A, IRIS Study Group: Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol; 2005 Jul;60(1):35-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
  • AIMS: This study was designed to investigate the biochemical and physiological covariates or comedications that affect the pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia (CP CML).
  • METHODS: Pharmacokinetic data were analyzed in 371 patients receiving 400 mg imatinib once daily during a phase III trial of imatinib vs interferon-alfa plus cytarabine for the treatment of newly diagnosed CP CML.
  • Blood samples for imatinib analysis were taken on treatment days 1 and 29.
  • Nonlinear mixed effects modelling was used for the population pharmacokinetic analysis.
  • Doubling body weight or Hb or halving the WBC count was associated with a 12%, 86% and 8% increase in CL, respectively, and a 32%, 60% and 5% increase in V, respectively.
  • CONCLUSIONS: Population covariates and coadministered drugs minimally affected imatinib pharmacokinetics in newly diagnosed CP CML patients.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Leukemia, Myeloid, Chronic-Phase / drug therapy. Piperazines / pharmacokinetics. Pyrimidines / pharmacokinetics

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1855-9 [14612892.001]
  • [Cites] J Clin Pharmacol. 2004 Feb;44(2):158-62 [14747424.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Br J Clin Pharmacol. 2004 Aug;58(2):212-6 [15255805.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):325-40 [11888061.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Clin Pharmacokinet. 1996 Feb;30(2):81-93 [8906893.001]
  • [Cites] J Pharmacokinet Biopharm. 1996 Oct;24(5):475-90 [9131486.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):379-86 [15592836.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):253-75 [11468940.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • (PMID = 15963092.001).
  • [ISSN] 0306-5251
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC1884912
  •  go-up   go-down


14. Serrano J, Prieto E, Mazarbeitia F, Román A, Llamas P, Tomás JF: Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT. Bone Marrow Transplant; 2001 Jan;27(1):85-7
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT.
  • She received interferon therapy for 25 months and it was discontinued when she developed skin lesions on her face and trunk, dysphagia and fever with respiratory failure and bilateral patchy airspace consolidation of the lung without microbiologic findings.
  • Histologic features showed discoid lupus erythematosis, oesophagitis with pseudomembranes and a mixed pattern of lymphocytic bronchiolitis involving the alveoli and interstitial spaces all compatible with chronic GVHD.
  • The patient was commenced on immunosuppressive therapy with complete clinical and radiological resolution.
  • To the best of our knowledge, this is the first case reported of severe chronic GVHD occurring during the course of interferon therapy for relapsed CML.
  • [MeSH-major] Graft vs Host Disease / chemically induced. Interferon-alpha / toxicity. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244442.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


15. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL: Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol; 2007 Sep;64(3):278-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.
  • AIMS: To characterize alemtuzumab pharmacokinetics and its exposure-response relationship with white blood cell (WBC) count in patients with B-cell chronic lymphocytic leukaemia (CLL).
  • METHODS: Nonlinear mixed effects models were used to characterize plasma concentration-time data and WBC count-time data from 67 patients.
  • Logistic regression was used to relate summary measures of drug exposure to tumour response.
  • The reduction in WBC over time was modelled by a stimulatory loss indirect response model with values of 18.2 for E(max), 306 microg l(-1) for EC(50), 1.56 x 10(9) cells l(-1) h(-1) for K(in) and 0.029 per h for K(out).
  • CONCLUSIONS: Alemtuzumab displayed time- and concentration-dependent pharmacokinetics with large interpatient variability, both in pharmacokinetics and pharmacodynamics, which was probably reflective of differences in tumour burden among patients.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Immunoglobulin G / blood. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / pharmacology. Dose-Response Relationship, Drug. Female. Humans. Leukocyte Count. Logistic Models. Male. Middle Aged. Models, Biological. Nonlinear Dynamics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Transplant. 2004 Apr;8(2):106-12 [15049789.001]
  • [Cites] Br J Clin Pharmacol. 2003 Sep;56(3):321-6 [12919181.001]
  • [Cites] J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78 [8133465.001]
  • [Cites] Clin Pharmacol Ther. 1994 Oct;56(4):406-19 [7955802.001]
  • [Cites] Br J Rheumatol. 1996 Mar;35(3):231-40 [8620297.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Mult Scler. 1996 Jul;1(6):357-65 [9345418.001]
  • [Cites] J Pharm Sci. 1998 Dec;87(12):1577-84 [10189270.001]
  • [Cites] Clin Pharmacol Ther. 1999 Sep;66(3):246-57 [10511060.001]
  • [Cites] Pharm Res. 2005 Jul;22(7):1088-100 [16028009.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2337-42 [16618945.001]
  • [Cites] J Pharmacokinet Biopharm. 1999 Aug;27(4):397-420 [10826130.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92 [11381569.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):231-52 [11468939.001]
  • [Cites] J Clin Pharmacol. 2001 Nov;41(11):1206-14 [11697753.001]
  • [Cites] J Immunol Methods. 2002 Feb 1;260(1-2):285-302 [11792397.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2712-9 [11929757.001]
  • [Cites] Clin Pharmacol Ther. 2002 Apr;71(4):235-45 [11956506.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Cytotherapy. 2001;3(4):261-7 [12171714.001]
  • [Cites] Clin Pharmacol Ther. 2003 Apr;73(4):348-65 [12709725.001]
  • [Cites] Blood. 2003 Jul 1;102(1):404-6 [12623851.001]
  • [Cites] Blood. 2004 Aug 15;104(4):948-55 [15090452.001]
  • (PMID = 17506867.001).
  • [ISSN] 0306-5251
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Immunoglobulin G; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2000651
  •  go-up   go-down


16. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G: A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res; 2008 Dec 15;14(24):8295-301
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The outcome of patients with refractory leukemia and myelodysplasia is poor, and new therapies are needed.
  • The antiapoptotic proteins of the Bcl-2 family are overexpressed in these malignancies and are potential therapeutic targets.
  • Therefore, we conducted a phase I clinical trial of the small-molecule pan-Bcl-2 inhibitor, obatoclax mesylate, in patients with refractory leukemia and myelodysplasia to assess its safety and define its optimal dose.
  • EXPERIMENTAL DESIGN: Forty-four patients with refractory leukemia or myelodysplasia were treated with obatoclax mesylate by continuous intravenous infusion at increasing doses and frequencies.
  • RESULTS: A total of 306 infusions of obatoclax mesylate were administered with a median of 5 infusions per patient.
  • The study drug was well tolerated up to the highest dose planned without dose-limiting toxicity.
  • Grade 1/2 central nervous system symptoms were the most common adverse events attributable to the study drug.
  • One patient with acute myeloid leukemia with mixed lineage leukemia t(9;11) rearrangement achieved a complete remission, which lasted 8 months.
  • CONCLUSIONS: Obatoclax mesylate is well tolerated and these results support its further investigation in patients with leukemia and myelodysplasia.
  • [MeSH-major] Leukemia / drug therapy. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Electrocardiography / drug effects. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088047.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrroles; 0 / obatoclax
  •  go-up   go-down


17. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet; 2004 Dec 18-31;364(9452):2181-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
  • We investigated the application of somatic gene therapy by use of a gibbon-ape-leukaemia-virus pseudotyped gammaretroviral vector.
  • Autologous CD34-positive haemopoietic bone-marrow stem cells were transduced ex vivo and returned to the patients without preceding cytoreductive chemotherapy.
  • FINDINGS: All patients have shown substantial improvements in clinical and immunological features, and prophylactic medication could be withdrawn in two.
  • INTERPRETATION: Gene therapy for SCID-X1 is a highly effective strategy for restoration of functional cellular and humoral immunity.
  • [MeSH-major] Genetic Diseases, X-Linked / therapy. Genetic Therapy. Severe Combined Immunodeficiency / therapy
  • [MeSH-minor] Antigens, CD34 / analysis. Bone Marrow Cells / immunology. Bone Marrow Transplantation. Child, Preschool. Gammaretrovirus. Gene Transfer Techniques. Genetic Vectors. Humans. Immunity. Immunoglobulins / blood. Infant. Interleukin Receptor Common gamma Subunit. Lymphocyte Activation. Lymphocyte Culture Test, Mixed. Mutation. Receptors, Interleukin-7 / genetics. T-Lymphocytes / immunology. Transduction, Genetic


18. Rezk H, el-Shazly AM, Soliman M, el-Nemr HI, Nagaty IM, Fouad MA: Coccidiosis among immuno-competent and -compromised adults. J Egypt Soc Parasitol; 2001 Dec;31(3):823-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was significant increase in coccidia positive cases among Hodgkin lymphoma receiving chemotherapy as compared to control group (p < 0.05).
  • The increase was highly significant in the group of acute lymphocytic leukaemia receiving chemotherapy as compared to control group (P < 0.01).
  • The total percent of cases with single type of coccidia were 12.2% compared to multiple coccidial infections (4.3%).
  • The total cryptosporidial infections (single and mixed with other coccidia) were 12.1% of the total studied cases.
  • Microsporidial infections (single and mixed with other coccidia), being the least detected among the four intestinal spores forming coccidia, were 2.4% in the immunocompromised groups.
  • The total cyclosporal infections (single and mixed with other coccidia) were 6.3% of the total studied cases.
  • Single cyclospora was 3.0% while mixed Cyclospora represented 3.3% of all studied cases.
  • The Isospora infections (single and mixed) were 3.8% of total patients.
  • [MeSH-minor] Adult. Aged. Animals. Antineoplastic Agents / adverse effects. Egypt / epidemiology. Female. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / immunology. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11775108.001).
  • [ISSN] 1110-0583
  • [Journal-full-title] Journal of the Egyptian Society of Parasitology
  • [ISO-abbreviation] J Egypt Soc Parasitol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Yamamura T, Ueda M, Psarras K, Suwa T, Watanaabe Y, Kameyama N, Tanabe M, Imamura H, Kitajima M: Immunosuppressive and anticancer effect of a mammalian ribonuclease that targets high-affinity interleukin-2-receptors. Eur J Surg; 2002;168(1):49-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL: Human lymphocytes isolated from healthy histoincompatible donors in mixed lymphocyte cultures or stimulated with phytohemagglutinin (PHA) to promote IL-2Ralpha expression.
  • 7G7B6-RNaseA also dose-dependently inhibited the human mixed lymphocyte reaction at an IC50 of 2 x 10(-6) M, whereas RNase alone did not.
  • However the conjugate had no inhibitory effect on the IL-2 receptor non-expressing human T-cell lymphoblastic leukaemia cell lines MOLT-4F or MT-1.
  • CONCLUSION: 7G7B6-RNaseA can inhibit cell proliferation in antigen- or mitogen-stimulated lymphocytes that overexpress high-affinity IL-2 receptors, and it may be safer than conventional chemotherapy or immunotoxins in the treatment of transplant rejection, certain lymphocytic malignancies, and other IL-2R-associated diseases, because it contains a mammalian cytotoxic enzyme.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Immunosuppressive Agents / pharmacology. Receptors, Interleukin-2 / drug effects. Ribonuclease, Pancreatic / pharmacology
  • [MeSH-minor] Animals. Cattle. Cell Division / drug effects. Humans. Lymphocyte Culture Test, Mixed. Lymphocytes / drug effects. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12022372.001).
  • [ISSN] 1102-4151
  • [Journal-full-title] The European journal of surgery = Acta chirurgica
  • [ISO-abbreviation] Eur J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Receptors, Interleukin-2; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


20. Jurado M, Deeg H, Gooley T, Anasetti C, Chauncey T, Flowers M, Myerson D, Storb R, Appelbaum F: Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol; 2001 Feb;112(2):392-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HSCT was performed because of progression to the spent phase of the disease with myelofibrosis and splenomegaly in 10 patients and evolution into a myelodysplastic syndrome (MDS) or acute myelogenous leukaemia (AML) in nine patients.
  • The interval from diagnosis to HSCT was 77-300 months (median 170).
  • Eleven patients received a transplant from a related, and eight from an unrelated, donor following conditioning with chemotherapy only or chemotherapy plus total body irradiation regimens.
  • Twelve patients are surviving 5-116 months (median 41) after transplant, 10 in continued complete remission, one in haematological remission with residual marrow fibrosis and one with mixed haemopoietic chimaerism currently receiving therapy with interferon.
  • These data show that HSCT can provide curative therapy for patients with PV and ET with advanced disease.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11167837.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA87948; United States / NHLBI NIH HHS / HL / HL36444
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


21. Pituch-Noworolska A: [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children]. Folia Med Cracov; 2001;42(3):5-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
  • [Transliterated title] Właściwości biologiczne i wrazliwość na leczenie indukcyjne komórek rozrostowych o nietypowym immunofenotypie w ostrych białaczkach u dzieci.
  • The atypical immunophenotype (expression of determinant from the another cell lines than line of origin) of acute leukaemia blast cells are noted in a part of cases.
  • The purpose of the study was: precise description of atypical immunophenotypes and analysis of their frequency in different types of acute leukaemia, analysis of association between expression of atypical immunophenotypes and the level of initial leukocytosis, percentage of blast cells in peripheral blood, expression of CD34, analysis of frequency of multidrug resistance molecule (MDR) expression and association between MDR and immunophenotypes of leukaemia cells, analysis of association between atypical immunophenotypes and proliferation, secretion of cytokines (IL-6, TNF) and spontaneous apoptosis of leukaemia cells, analysis of association between atypical immunophenotypes and sensitivity to induction therapy.
  • The bone marrow samples used for routine diagnosis were the basic source of leukaemia cells for the study.
  • The morphological examination and the immunophenotypes of leukaemia cells were done for classification of leukaemia.
  • The spontaneous proliferation of leukaemia cells was studied with 3H-Thymidine uptake after 3-days culture in vitro.
  • The type of proliferation (autocrine, paracrine) was defined based on comparison of shorter (3-days) and longer (6-days) culture of leukaemia cells.
  • The percentage of apoptotic leukaemia cells was analysed with flow cytometry after staining of leukaemia cells with propidium iodide in subdiploidal region of DNA profile.
  • The secretion of cytokines (IL-6 and TNF) was determined by ELISA technique in supernatants of leukaemia cells cultured for 24 hr in vitro.
  • The effect of induction therapy was estimated base on time of cytoreduction in peripheral blood and time of reaching the haematological remission in bone marrow.
  • The study included 230 children with acute leukaemia: lymphoblastic (ALL)--189 children (ALL-proB--19, common ALL--139, ALL-B--5 and ALL-T--26) and myeloid (AML)--34 children.
  • Moreover, into the study 2 cases of acute undifferentiated leukaemia (AUL) and 3--acute mixed lineage leukaemia (AMLL) and 2--biphenotypic leukaemia were included.
  • The all studies of leukaemia cells had been done before the therapy was installed.
  • Basing on the assay of immunophenotypes the following forms of atypical immunophenotypes were distinguished: immunophenotype incomplete, hyperexpression of determinants, asynchronic immunophenotype, coexpression of determinants from the other line than origin of leukaemia cells, balanced expression of determinants from two cells lines (biphenotypic leukaemia) and three cells lines (mixed lineage leukaemia).
  • The expression of CD34, recognised as the one of markers of poorer prognosis, was analysed regarding the leukaemia type and immunophenotype of leukaemia cells.
  • The common ALL + My leukaemia cells showed higher ability to proliferation in vitro compare with common ALL without atypical immunophenotype.
  • AML leukaemia cells with coexpression of lymphoid determinants (AML + Ly) showed lower proliferation in vitro than AML without atypical immunophenotype.
  • The autocrine type of proliferation was observed frequently in AML (35.3% of cases) than in ALL (14.2%).
  • This type of spontaneous proliferation was observed only when the leukaemia cells without changes in immunophenotype had been cultured.
  • AML leukaemia cells without changes in immunophenotype released significantly higher amount of these cytokines than AML cells with atypical immunophenotypes (AML + Ly).
  • The ALL + My leukaemia cells behaved similarly to myeloid leukaemia cells, while AML + Ly cells showed features of lymphoid leukaemia cells.
  • The common ALL and AML leukaemia cells with atypical immunophenotype showed higher percentage of apoptotic cells (16.1% and 16.9% respectively) comparing to common ALL and AML without changes in immunophenotype (9.0% and 9.2% respectively).
  • In common ALL and AML with typical immunophenotype of leukaemia cells and ALL-T the level of apoptosis was associated positively with the spontaneous proliferation, whereas this relation was negative in AML with atypical immunophenotype.
  • There were no differences of the time of cytoreduction of leukaemia cells in peripheral blood in B cell origin ALL and AML with or without changes in immunophenotype of blastic cells.
  • In ALL-T + My the time of cytoreduction was significantly longer.
  • However, the expression of CD10 in ALL-T had no effect on cytoreduction time.
  • The expression of MDR in ALL-T with typical immunophenotype was independent marker associated with elongation of cytoreduction time.
  • The time of reaching the complete haematological remission was analysed in 186 children with ALL (ALL-proB--18 children, common ALL--137 children, ALL-T--26) and only 19 children with AML.
  • The longest period of time for reaching the remission was observed in AML, shortest--in ALL-T.
  • In common ALL and ALL-T the expression of myeloid determinants was associated with significant elongation of time of reaching the remission.
  • The time needed for the reaching of remission was similar in AML with or without coexpression of lymphoid determinants.
  • The results of this study suggest that coexpression of determinants from the other cell line modify the biological properties of leukaemia cells into the cells from the line of origin of these additional determinants.
  • In ALL the combined expression of MDR and atypical immunophenotype of leukaemia cells were associated with poorer response to induction therapy.
  • In AML the combined expression of CD34 and atypical immunophenotype were associated with response to induction therapy by reaching the complete remission, but without any influence on the time of reaching this remission.
  • The results of analysis of cytoreduction time and time of reaching the remission improved the usefulness of these parameters for the estimation of response to the induction therapy.
  • The clinical importance of these observations consist in characterisation of leukaemia cells potentially resistant to the induction therapy what may suggest the modification and individualization of the induction therapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Animals. Antigens, CD34 / immunology. Apoptosis. Child. Child, Preschool. Cytokines / secretion. Drug Resistance, Multiple / immunology. Humans. Immunophenotyping. Infant. Mice. Multidrug Resistance-Associated Proteins / immunology. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12353422.001).
  • [ISSN] 0015-5616
  • [Journal-full-title] Folia medica Cracoviensia
  • [ISO-abbreviation] Folia Med Cracov
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Cytokines; 0 / Multidrug Resistance-Associated Proteins
  • [Number-of-references] 160
  •  go-up   go-down


22. Avramis VI, Panosyan EH: Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet; 2005;44(4):367-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Asparaginase activity of 0.1 IU/mL provided insufficient depletion of both amino acids in high-risk acute lymphoblastic leukaemia (ALL) patients.
  • With increasing glutamine deamination, mean asparaginase activities and percentages of post-treatment samples with effective ASN depletion (<3 micromol/L) increase.
  • Further population analyses resulted in identification of sigmoid relationships between asparaginase levels and post-treatment glutamine and ASN deamination.Furthermore, pharmacodynamic analyses strongly suggested that >/=90% deamination of glutamine must occur before optimal ASN deamination takes place, due to the de novo ASN biosynthesis by the liver.
  • These pharmacodynamic results from the best-fit population pharmacokinetic/pharmacodynamic model obtained from nonlinear mixed effects model pharmacodynamic analyses for standard-risk ALL patients are similar.
  • These results taken together strongly support new experimental approaches for application of population pharmacokinetic/pharmacodynamic analyses to further enhance survival of leukaemia patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Child. Clinical Trials as Topic. Drug Administration Schedule. Drug Resistance, Neoplasm. Escherichia coli / enzymology. History, 20th Century. History, 21st Century. Humans. Pectobacterium chrysanthemi / enzymology. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / pharmacology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematol Blood Transfus. 1990;33:619-26 [2182452.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1971;40(3):463-9 [4993767.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer. 1978 Nov;42(5):2123-34 [363252.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Summer;8(2):99-104 [3526939.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:147-50 [8481663.001]
  • [Cites] Br J Clin Pharmacol. 2001 Oct;52(4):433-7 [11678787.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):675-81 [9074406.001]
  • [Cites] J Biol Chem. 1976 Sep 10;251(17):5375-80 [956189.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1176-81 [7850718.001]
  • [Cites] Arch Biochem Biophys. 1964 May;105:450-2 [14186753.001]
  • [Cites] In Vivo. 2001 Jan-Feb;15(1):1-9 [11286117.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):115-9 [11328290.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1977;17:97-116 [326177.001]
  • [Cites] Cancer. 1970 Feb;25(2):241-3 [4905151.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2774-82 [12065553.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10 (16):5335-41 [15328169.001]
  • [Cites] J Natl Cancer Inst. 1965 Dec;35(6):967-74 [5856684.001]
  • [Cites] Cancer Res. 1966 Feb;26(2):208-11 [5903173.001]
  • [Cites] Haematol Blood Transfus. 1981;26:87-93 [6947941.001]
  • [Cites] Proc Natl Acad Sci U S A. 1966 Nov;56(5):1516-9 [5339624.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5601-7 [6352020.001]
  • [Cites] Br J Haematol. 2000 Aug;110(2):379-84 [10971395.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Aug;50(2):117-20 [12172975.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48(2):123-33 [11561778.001]
  • [Cites] J Exp Med. 1963 Jul;118:99-120 [14015821.001]
  • [Cites] Biochim Biophys Acta. 1975 Feb 24;383(1):30-9 [1173050.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):794-9 [11564065.001]
  • [Cites] J Vet Intern Med. 1992 Jul-Aug;6(4):230-4 [1522554.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):3-5 [10029804.001]
  • [Cites] Lancet. 1988 Oct 22;2(8617):921-4 [2902379.001]
  • [Cites] Cancer Res. 1987 Mar 1;47(5):1313-8 [2434214.001]
  • [Cites] J Exp Med. 1953 Dec;98(6):565-82 [13109110.001]
  • [Cites] Blood. 1994 Jul 15;84(2):355-66 [8025264.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):327-37 [11908926.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] JAMA. 1971 Apr 26;216(4):648-52 [5279904.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Feb;49(2):149-54 [11862429.001]
  • [Cites] Lancet. 1968 Oct 5;2(7571):776-7 [4175572.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7 [11902303.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Jul;48(1):77-82 [11488528.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1072-7 [15057247.001]
  • [Cites] Proc Soc Exp Biol Med. 1965 Jun;119:325-7 [14328879.001]
  • [Cites] J Exp Med. 1966 Jan 1;123(1):55-74 [5902571.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1525-32 [10735901.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1709-15 [10961868.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2734-9 [11929760.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Int J Clin Pharmacol Ther. 1997 Mar;35(3):96-8 [9088996.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2904-5 [9738556.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):11-22 [11299723.001]
  • [Cites] Cancer Treat Rep. 1981;65 Suppl 4:123-30 [7049376.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1527-33 [9766495.001]
  • [Cites] J Exp Med. 1968 Jun 1;127(6):1055-72 [4871211.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Cancer Res. 1985 Jan;45(1):217-20 [2578094.001]
  • [Cites] Biochemistry. 1966 May;5(5):1605-12 [5335809.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4554-8 [6895481.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):313-20 [10050714.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2619-31 [5237354.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S44-9 [11858964.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):310-6 [11979454.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1780-6 [8355045.001]
  • [Cites] Eur J Cancer. 1996 Aug;32A(9):1544-50 [8911116.001]
  • [Cites] Cancer. 1973 Sep;32(3):585-97 [4516634.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1845-53 [9058703.001]
  • [Cites] Int J Pharm. 2001 Apr 17;217(1-2):215-24 [11292557.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):983-90 [11843837.001]
  • [Cites] Leukemia. 2003 Aug;17 (8):1583-8 [12886246.001]
  • [Cites] Curr Opin Hematol. 1995 Jul;2(4):240-6 [9372003.001]
  • [Cites] Cancer Treat Rep. 1981;65 Suppl 4:111-4 [7049374.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B73-6 [11757713.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • (PMID = 15828851.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 7D96IR0PPM / pegaspargase; EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 88
  •  go-up   go-down


23. Perkhofer S, Lass-Flörl C, Hell M, Russ G, Krause R, Hönigl M, Geltner C, Auberger J, Gastl G, Mitterbauer M, Willinger B, Knöbl P, Resch G, Waldner R, Makrai A, Hartmann G, Girschikofsky M, Greil R: The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents; 2010 Dec;36(6):531-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.
  • A prospective, observational, multicentre study was performed to assess the incidence, diagnosis, epidemiology and outcome of invasive mould infections (IMIs) reported to the Nationwide Austrian Aspergillus Registry.
  • Patients with acute myelogenous leukaemia (34%) and lung transplant recipients (17%) are currently at highest risk for IMI, followed by a mixed population with impaired immunity (14%).
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillosis / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Austria / epidemiology. Female. Humans. Immunocompromised Host. Incidence. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
  • (PMID = 20947312.001).
  • [ISSN] 1872-7913
  • [Journal-full-title] International journal of antimicrobial agents
  • [ISO-abbreviation] Int. J. Antimicrob. Agents
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


24. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T: Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer; 2008 May 20;98(10):1633-40
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST).
  • Using a nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate imatinib exposure (area under the curve, AUC) in 58 patients.
  • Both total (in GIST) and free drug exposure (in CML and GIST) correlated with the occurrence and number of side effects (e.g. odds ratio 2.7+/-0.6 for a two-fold free AUC increase in GIST; P<0.001).
  • Higher free AUC also predicted a higher probability of therapeutic response in GIST (odds ratio 2.6+/-1.1; P=0.026) when taking into account tumour KIT genotype (strongest association in patients harbouring exon 9 mutation or wild-type KIT, known to decrease tumour sensitivity towards imatinib).
  • Our findings represent additional arguments to further evaluate the usefulness of individualizing imatinib prescription based on a therapeutic drug monitoring programme, possibly associated with target genotype profiling of patients.
  • [MeSH-major] Antineoplastic Agents / blood. Antineoplastic Agents / pharmacology. Gastrointestinal Stromal Tumors / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / blood. Piperazines / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / blood. Pyrimidines / pharmacology
  • [MeSH-minor] Adult. Aged. Area Under Curve. Benzamides. Female. Genotype. Humans. Imatinib Mesylate. Logistic Models. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Protein Kinase Inhibitors / blood. Protein Kinase Inhibitors / pharmacology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 15;66(10):1907-13 [14599548.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):618-9 [11529225.001]
  • [Cites] Drug Resist Updat. 2003 Oct;6(5):231-8 [14643293.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):689-95 [15010069.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):285-92 [15063337.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1321-31 [15215876.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3739-45 [15315971.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):12-9 [15671523.001]
  • [Cites] Expert Opin Pharmacother. 2005 Jan;6(1):105-13 [15709888.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):379-86 [15592836.001]
  • [Cites] Neoplasma. 2005;52(1):63-7 [15739029.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4182-90 [15930355.001]
  • [Cites] Br J Clin Pharmacol. 2005 Jul;60(1):35-44 [15963092.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1133-4; author reply 1134 [16033955.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1751-7 [16098458.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):744-8 [16160693.001]
  • [Cites] Dermatology. 2005;211(4):363-5 [16286749.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1093-103 [16624552.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Nat Med. 2006 Aug;12(8):908-16 [16862153.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6073-8 [17062683.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7180-6 [17145844.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):192-4 [17284712.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1834-8 [17519908.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jul;82(1):33-40 [17495881.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1561-2; author reply 1562-4 [17429432.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1699-701; author reply 1701 [17712052.001]
  • [Cites] Clin Pharmacol Ther. 2008 Feb;83(2):258-64 [17568400.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):563-9 [18235115.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):570-6 [18235116.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):620-5 [18235121.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] J Mass Spectrom. 2008 Jun;43(6):736-52 [18286663.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):712-3 [11870257.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):625-32 [12576428.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2368-73 [12609962.001]
  • [Cites] Expert Opin Pharmacother. 2003 Jun;4(6):963-71 [12783592.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):438-45 [12850195.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 18;92(20):1641-50 [11036109.001]
  • (PMID = 18475296.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC2391118
  •  go-up   go-down


25. Lacy A, O'Kennedy R: Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des; 2004;10(30):3797-811
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer.
  • It is estimated that the average western diet contains approximately 1 g/day of mixed benzopyrones.
  • It is, therefore, not difficult to see why extensive research into their pharmacological and therapeutic properties is underway over many years.
  • Therefore, the focus will be on these relevant compounds and their therapeutic importance.
  • A recent study has shown that 7-hydroxycoumarin inhibits the release of Cyclin D1, which is overexpressed in many types of cancer.
  • This knowledge may lead to its use in cancer therapy.
  • Esculetin inhibits growth and cell cycle progression by inducing arrest of the G(1) phase in HL-60 leukaemia cells, resulting from the inhibition of retinoblastoma protein phosphorylation.
  • Recent studies investigating the potential of flavonoids as therapeutic agents have suggested they may have use in various therapeutic settings ranging from leukaemia treatment to the treatment of patients with HIV.
  • Studies have indicated that genistein elicits inhibitory effects on cell growth of various carcinoma cell-lines and may be a potential candidate for cancer therapy.
  • Microtitre assays were performed along with real-time analysis of cell viability using a biosensor called the Cytosensor microphysiometer.
  • [MeSH-major] Coumarins. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Biotransformation. Clinical Trials as Topic. Humans. Molecular Structure. Treatment Outcome


26. Eiden C, Peyrière H, Tichit R, Cociglio M, Amedro P, Blayac JP, Margueritte G, Hillaire-Buys D: Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther; 2007 Jun;32(3):321-4
Genetic Alliance. consumer health - Long QT Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited long QT syndrome revealed by antifungals drug-drug interaction.
  • A 14-year-old Tahitian girl with acute myeloid leukaemia and a suspected mucormucosis infection was treated with intravenous voriconazole and caspofungin.
  • The association of antifungal agents with pro-arrhythmogenic drugs and other risk factors led to torsades de pointes and the revealing of inherited QT syndrome.
  • [MeSH-minor] Acute Disease. Adolescent. Aryl Hydrocarbon Hydroxylases / genetics. Cytochrome P-450 CYP2C19. Cytochrome P-450 CYP2C9. Female. Genotype. Humans. Injections, Intravenous. Leukemia, Myeloid / complications. Mixed Function Oxygenases / genetics. Mucormycosis / complications. Mucormycosis / drug therapy. Pyrimidines / administration & dosage. Pyrimidines / adverse effects. Pyrimidines / therapeutic use. Triazoles / administration & dosage. Triazoles / adverse effects. Triazoles / therapeutic use. Voriconazole

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489884.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 6TK1G07BHZ / posaconazole; EC 1.- / Mixed Function Oxygenases; EC 1.14.13.- / CYP2C9 protein, human; EC 1.14.13.- / Cytochrome P-450 CYP2C19; EC 1.14.13.- / Cytochrome P-450 CYP2C9; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2C19 protein, human; JFU09I87TR / Voriconazole
  •  go-up   go-down


27. Glodkowska E, Bialas A, Jackowska T: [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia]. Med Wieku Rozwoj; 2007 Apr-Jun;11(2 Pt 1):153-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
  • INTRODUCTION: Acute lymphoblastic leukaemia (ALL) is one of the most common cancers in children.
  • In Poland, since November 2002 a new protocol of risk stratification has been recommended for assessment of risk factors and for choosing therapy regimens.
  • The stratification was by age, leukocyte count, cytogenetic changes, early response to prednisone therapy and bone marrow remission.
  • RESULTS: out of the 100 patients qualified for treatment regimens according to the ALL-IC 2002 protocol, 97 entered remission, 11 died and 3 had a relapse.
  • According to the BFM-90 protocol 18/31 (58%) and 16/44 (36%) patients from the SR and IR groups respectively would be given more intensive treatment.
  • On the other hand 11/44 (25%) and 14/25 (56%) patients from the IR and HR groups respectively would be given less intensive treatment.
  • This is linked to basic change of treatment protocol, adequate to severity of disease.
  • 2. Children with ALL qualified according to protocol BFM-90 for moderate risk group (IR) constitute a mixed group in the ALL-IC 2002 classification.
  • 3. Further studies are needed on stratification validity according to ALL-IL 2002 and on the need of further modification (eg assessment of additional factors) in order to decide on the best treatment, adequate to severity of disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Risk Assessment / methods
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Humans. Infant. Male. Poland. Prednisolone / therapeutic use. Prednisone / therapeutic use. Prognosis. Remission Induction. Salvage Therapy / methods. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625285.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol; PVDA protocol
  •  go-up   go-down


28. Ng A, Ravetto PF, Taylor GM, Wynn RF, Eden OB: Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis. Br J Cancer; 2004 Dec 13;91(12):1990-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis.
  • Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement.
  • By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis.
  • This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. DNA-Binding Proteins / genetics. Histiocytosis, Non-Langerhans-Cell / drug therapy. Leukemia, Myelomonocytic, Acute / etiology. Neoplasms, Second Primary / genetics. Nucleic Acid Synthesis Inhibitors / adverse effects. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Blotting, Southern. Dexamethasone / administration & dosage. Epstein-Barr Virus Infections / complications. Etoposide / adverse effects. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Infant. Male. Methotrexate / administration & dosage. Myeloid-Lymphoid Leukemia Protein. Polymerase Chain Reaction. Time Factors. Topoisomerase II Inhibitors

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2814-9 [10706619.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] Med Pediatr Oncol. 2001 Aug;37(2):153-4 [11496359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9802-7 [11493704.001]
  • [Cites] Int J Hematol. 1998 Oct;68(3):333-6 [9846019.001]
  • [Cites] Med Pediatr Oncol. 1997 May;28(5):342-7 [9121398.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Leukemia. 1998 Jun;12(6):976-81 [9639429.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]
  • (PMID = 15570305.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Topoisomerase II Inhibitors; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2409780
  •  go-up   go-down


29. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T, Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT): Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia; 2003 Sep;17(9):1707-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
  • We studied 128 patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (SCT).
  • Disease at the time of treatment with Imatinib was in chronic phase (CP) in 51 patients, accelerated phase (AP) in 31 and blastic crisis (BC) in 46.
  • The median interval between relapse and Imatinib therapy was 5 months (0-65).
  • A total of 50 patients had failed treatment with donor lymphocyte infusions prior to Imatinib.
  • With a median follow-up of 9 months, the estimated 2-year survival for CP, AP and BC patients was 100, 86 and 12%, respectively.
  • Out of 79 evaluable patients, 45 (57%) achieved full donor and 11 (14%) mixed chimerism after Imatinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Female. Graft vs Leukemia Effect. Humans. Imatinib Mesylate. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Transplantation, Homologous. Treatment Outcome


30. McLintock LA, Gibson BE, Jones BL: Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia. Br J Haematol; 2005 Mar;128(6):737
MedlinePlus Health Information. consumer health - Aspergillosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia.
  • [MeSH-major] Absidia. Aspergillosis / complications. Aspergillus fumigatus. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications. Mucormycosis / complications
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Drug Therapy, Combination. Humans. Male. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755275.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down






Advertisement